Annexon, Inc.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the classical complement pathway, an immune system mechanism implicated in autoimmune and neuroinflammatory diseases. Its lead program, ANX1502, is an oral small-molecule inhibitor being studied in cold agglutinin disease and other complement-mediated autoimmune indications. The company was incorporated in 2011 and has remained in the research-and-development phase, with no approved products and no product revenue to date. Annexon’s business model is centered on advancing product candidates through clinical development and, if successful, eventually commercializing them directly or through partners.

5.68

5.68

— Annexon, Inc.
%
Lead drug candidate development100% Development of ANX1502 and related clinical-stage assets targeting complement-mediated disease.
Preclinical and translational research0% Discovery, biomarker, and early-stage research used to select indications and support clinical advancement.
Clinical trial operations0% Execution of Phase 1 and proof-of-concept studies through third-party sites, CROs, and consultants.
Regulatory development support0% Work needed to prepare regulatory submissions and eventual commercialization readiness.

Annexon does not currently sell approved products, so it has no commercial customer base today...

  • Clinical development partnersprimary

    CROs, trial sites, consultants, and manufacturers that support discovery, testing, and regulatory preparation.

  • Trial patientsprimary

    Patients enrolled in CAD and other autoimmune studies who generate safety, PK, PD, and efficacy data.

  • Specialty physicianssecondary

    Hematology, immunology, and other specialists who would prescribe ANX1502 if approved.

  • Payers and insurerssecondary

    Commercial and government payers that influence reimbursement, pricing, and market access after approval.

Annexon is headquartered in the United States and conducts its development activities from a U.S. base...

  • •Headquartered and incorporated in the United States
  • •Current operations are centered on U.S.-based R&D and clinical development
  • •Future commercialization would need to cover the U.S. and foreign markets
  • •No product sales revenue disclosed, so no country revenue mix exists yet
  • •Geographic exposure is mainly regulatory and clinical-trial related

Annexon's strategy is to advance ANX1502 through clinical proof-of-concept and expand into additional...

01
Complete clinical proof-of-concept for ANX1502short-term

Clinical data are needed to validate mechanism, safety, and efficacy before broader development or partnering.

02
Expand into additional complement-mediated autoimmune diseasesmedium-term

A broader indication set could increase the commercial opportunity if the molecule proves effective.

03
Build or source commercialization capabilitiesmedium-term

Approval would require sales, distribution, and market access execution that the company does not currently have.

Annexon is exposed to the classic risks of a clinical-stage biotech: no approved products, no product revenue, and...

critical

Clinical development failure

ANX1502 must demonstrate safety, pharmacodynamics, and clinical efficacy before it can be approved or commercialized.

Scope
Lead program ANX1502 and future autoimmune indications
Materiality
high
high

No commercial infrastructure

The company currently has no marketing or sales organization, so launch would require costly build-out or partnering.

Scope
Future product commercialization
Materiality
high
high

Financing and liquidity dependence

The company has incurred losses since inception and funds operations primarily through equity financing.

Scope
Corporate funding and runway
Materiality
high
high

Competition and market timing

Larger competitors may reach the market sooner or offer alternative therapies with better efficacy, safety, or pricing.

Scope
Complement-mediated autoimmune disease markets
Materiality
medium
medium

Reimbursement and access risk

Even if approved, payer coverage and pricing policies will determine whether patients can access the therapy.

Scope
Commercial launch and adoption
Materiality
medium
Research and development accruals
Can shift quarterly operating loss and accrued expenses
Stock-based compensation
Influences reported operating loss and non-cash expense
Fair value of investments and cash equivalents
Affects other income and liquidity presentation
Clinical-stage cost volatility
Reduces comparability across quarters

Ventyx Biosciences, Inc.

Pharmaceutical Preparations

BioXcel Therapeutics, Inc.

BTAI · Pharmaceutical Preparations

AN2 Therapeutics, Inc.

ANTX · Pharmaceutical Preparations

ALX ONCOLOGY HOLDINGS INC

ALXO · Pharmaceutical Preparations

Immix Biopharma, Inc.

IMMX · Pharmaceutical Preparations

Janux Therapeutics, Inc.

JANX · Pharmaceutical Preparations

: 11/08/2026